Imidazolopiperazines: lead optimization of the second-generation antimalarial agents (Publications)
mice. The optimized compounds were found to be more efficacious than the current antimalarials in a malaria mouse model. They exhibit moderate oral exposure in rat pharmacokinetic studies to achieve sufficient
Quantifying the impact of interventions against <em>Plasmodium vivax</em>: a model for country-specific use (Publications)
fictitious data, by simulating and comparing the impact of various intervention combinations on malaria risk and burden, this model could be a useful tool for strategic planning, implementation and resource
A Tireless Leader (Page)
https://www.swisstph.ch/de/news/20160601-a-tireless-leader
now represented in leading consortia for global health such as the Roll Back Malaria Partnership, the Medicines for Malaria Venture (MMV), the Drugs for Neglected Diseases initiative (DNDi) and the Bill [...] Many return to their country of origin and continue the fight against diseases of poverty such as malaria, tuberculosis and HIV/AIDS in leading functions in health care. “Educating young people from the [...] : all possible means will have to be mobilised in the fight against diseases of...
Symposium Professorship in Neglected Tropical Diseases (News)
https://www.swisstph.ch/de/news/news-detail-1/news/symposium-professorship-in-neglected-tropical-diseases
Université de Fribourg Extracellular vesicles in the regulation of host-pathogen interactions during malaria 11:10 – 11:50 Dr. Catherine Ronet Université de Lausanne Leishmania-RNA virus subverts the host immune
Synthesis and antiprotozoal activity of azabicyclo-nonane pyrimidine hybrids (Publications)
protozoan parasites. A series of fused hybrids were synthesized and tested in vitro against pathogens of malaria tropica and sleeping sickness. The activities and selectivities of compounds strongly depended on
Translation of liver stage activity of M5717, a <em>Plasmodium</em> elongation factor 2 inhibitor: from bench to bedside (Publications)
stage of Plasmodium infection through chemoprevention could become a key intervention to reduce malaria-associated incidence and mortality. METHODS: M5717, a Plasmodium elongation factor 2 inhibitor, was
Ancistrotanzanine C and related 5,1'- and 7,3'-coupled naphthylisoquinoline alkaloids from <em>Ancistrocladus tanzaniensis</em> (Publications)
and chiroptical methods. The biological activities of the alkaloids against the pathogens causing malaria tropica, leishmaniasis, Chagas' disease, and African sleeping sickness were evaluated
New 2‑aminopyrimidine derivatives and their antitrypanosomal and antiplasmodial activities (Publications)
of sleeping sickness, Trypanosoma brucei rhodesiense, as well as against a causative organism of malaria, Plasmodium falciparum NF54. Their cytotoxic properties were determined with L-6 cells (rat skeletal
Phytochemical study and antiprotozoal activity of compounds isolated from <em>Thalia geniculata</em> (Publications)
Thalia geniculata L. (Marantaceae) is an African medicinal plant traditionally used in Benin to treat malaria and other parasitic diseases. There is little ethnobotanical and almost no chemical information available
Abnormal blood glucose concentrations on admission to a rural Kenyan district hospital: prevalence and outcome (Publications)
a on admission was 7.3%. Severe illness, malnutrition, last meal > 12 hours ago, and a positive malaria slide were independently associated with hypoglycaemia. Overall, mortality in hypoglycaemic children